Skip to main content

Genetic Improvement is Bright

The future of poultry genetic improvement is bright

Poultry genetics companies are prioritizing new research and technology to meet the needs of hungry consumers worldwide.


Genetics have improved significantly across all sectors of agriculture over the last few decades, from feed ingredients, to cotton production and in animal agriculture, especially in the broiler industry, explained genetics company Cobb Research and Development Vice President William Herring at the 2024 Chicken Marketing Summit.

“We're becoming more efficient. We're doing more with less resources,” he stated. “I don't think there's any end in sight to genetic progress or genetic change. We don't see that across agriculture anywhere, and we certainly don't see it in broiler genetics.”

To help advance poultry genetics further, Cobb created a program called “Cobb’s Proving Grounds,” which is focused on generating a large amount of data to improve its currents products and create new ones.

According to Herring, the initiative is multiplying its product data capabilities by 50 to quickly improve the genetic progress it can make in poultry. To do so, Cobb is utilizing multiple genetic research facilities with large-scale capabilities and environments comparable to commercial production conditions around the world.

Herring said that Cobb placed the first parent stock in April 2024, the second in August 2024 and it plans to place a third in February 2025 to ensure its genetic improvements are scalable on a commercial level and product consistent results.

“It's meant to generate data that one can have confidence in,” he added.

Genetics has always been a subject that is slightly over my head; it can be confusing when you start talking about how it all really works. However, it is encouraging to see how far poultry genetics have come, witness the impact they have had on the supply chain and wonder about where they are going to go next.

Attend the 2025 Chicken Marketing Summit

The 2025 Chicken Marketing Summit will be held at the DeSoto Savannah in Savannah, Georgia, on July 28-30, 2025.

Serving a unique cross-section of the chicken supply chain, the Chicken Marketing Summit explores issues and trends in food marketing and consumer chicken consumption patterns and purchasing behavior.

dual gene therapy, FKRP, FST, LGMDR9, Limb-Girdle Muscular Dystrophy, ambulation, muscle strength, pathology, gene expression, mouse model, muscular dystrophy, Fukutin-Related Protein, Follistatin, therapeutic approach, muscle function, neuromuscular disease, genetic treatment, dystroglycanopathy, muscle regeneration, preclinical study,

#DualGeneTherapy, #FKRP, #FST, #LGMDR9, #MuscularDystrophy, #Ambulation, #MuscleStrength, #Pathology, #GeneExpression, #MouseModel, #FukutinRelatedProtein, #Follistatin, #TherapeuticApproach, #MuscleFunction, #NeuromuscularDisease, #GeneticTreatment, #Dystroglycanopathy, #MuscleRegeneration, #PreclinicalStudy, #GeneTherapy

International Conference on Genetics and Genomics of Diseases 




For Enquiries: genetics@healthcarek.com 

Get Connected Here 
--------------------------------- 
--------------------------------- 
facebook.com/profile.php?id=61555903296992 
tumblr.com/blog/dorita0211 

Comments

Post a Comment

Popular posts from this blog

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Post-Stroke Cardiovascular risks

Study finds genetic factors key to post-stroke cardiovascular risks In a recent study published in the journal Stroke , researchers identify genetic and molecular risk factors for subsequent cardiovascular outcomes after incident stroke in an effort to identify potential therapeutic targets to improve patient prognoses. Identifying the causes of stroke Stroke is a major global health issue that causes significant disability and mortality, particularly arterial ischemic stroke (AIS). AIS, which is a type of stroke caused by blocked blood flow to the brain, is responsible for up to 85% of stroke cases. AIS arises due to cerebral blood vessel blockage, with modifiable risk factors including hypertension, diabetes, dyslipidemia, atrial fibrillation, obesity, and lifestyle behaviors. Although genome-wide association studies (GWAS) often focus on incident strokes, studying subsequent events can provide new insights into stroke progression. Further research is crucial to identify genetic and...
Post a Comment
Read more

Type of Inherited Blindness in Dogs

Genetic test could eradicate a type of inherited blindness in dogs A mountain rescue dog whose duties ended after her eyesight failed has helped scientists create a test that could eradicate the genetic eye condition in her breed for good. Shola the English shepherd has an inherited eye disease called progressive retinal atrophy (PRA) that causes the light-sensitive cells at the back of the eye to deteriorate, eventually leading to blindness. PRA affects more than 100 dog breeds, can be caused by a number of different genetic variants and has no treatment. For some types, symptoms do not appear until the dog is several years old , by which point they may have passed their genes on to puppies. Katherine Stanbury, the first author of the research from the University of Cambridge, said Shola was four years old when she began struggling with her vision in dim light. “She was sent to a veterinary ophthalmologist and they confirmed that she had PRA,” said Stanbury. “And then it turned out h...
Post a Comment
Read more